Pek, M <br/><br/>
Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.  [electronic resource] 

 -  Oncogene  08 2017 
 - 4975-4986 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2017.120  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Benzamides--pharmacology<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Colorectal Neoplasms--drug therapy<br/>Cyclin-Dependent Kinase 4--antagonists & inhibitors<br/>Cyclin-Dependent Kinase 6--antagonists & inhibitors<br/>Diphenylamine--analogs & derivatives<br/>Female<br/>Gene Expression Profiling<br/>HCT116 Cells<br/>HT29 Cells<br/>Humans<br/>MAP Kinase Kinase Kinases--antagonists & inhibitors<br/>Mice<br/>Mice, Inbred NOD<br/>Mice, SCID<br/>Molecular Targeted Therapy<br/>Piperazines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Pyridines--pharmacology<br/>Random Allocation<br/>Xenograft Model Antitumor Assays